As with GSK before it, Daewoong Bio’s manufacturing misstep has resulted in a ban for the Korean company from China’s bulk-buy drug procurement program.
Fierce Pharma
Internet News
New York, New York 90,926 followers
Pharma’s go-to destination for news & trends shaping approved drugs.
About us
Fierce Pharma is the go-to destination for the news and trends shaping the industry. Our focus daily is on news about approved drugs and every aspect of pharma’s operations as well as the people who move pharma forward. Our coverage also feeds longer-form content, podcasts and events. In staying on top of the news, our journalists have developed a loyal audience. Critically, we explain the news—often complicated technology or business maneuvers—and put it in context that brings it home for our readers and listeners in their work lives. Delivering news, revealing insights straight to your inboxes: https://fiercepharma.questexinfo.com/loading.do?omedasite=Pharma_full. Our family of publications includes Fierce Pharma, Fierce Pharma PM Tracker, Fierce Pharma Marketing, Fierce Manufacturing, Fierce Drug Delivery and Fierce Life Sciences Weekly Digest. Follow our podcast ‘The Top Line’ on Apple Podcasts, Spotify, Amazon, iHeart or wherever you get your podcasts. We dig into high-impact trends and recount the week’s biggest headlines. For Biotech news you can’t miss: https://www.linkedin.com/showcase/fierce-biotech For Healthcare news you can’t miss: https://www.linkedin.com/showcase/fierce-healthcare
- Industry
- Internet News
- Company size
- 51-200 employees
- Headquarters
- New York, New York
- Type
- Privately Held
- Founded
- 2006
Locations
-
Primary
685 3rd Ave
21st Floor
New York, New York 10017, US
Employees at Fierce Pharma
Updates
-
This week on "The Top Line," we dive into the current state and implications of Novo Holdings' proposed $16.5 billion buyout of Catalent. Former FTC policy director David Balto joins Fierce Pharma’s Fraiser Kansteiner for this episode.
Former FTC director weighs in on Novo's $16.5B deal with Catalent
fiercepharma.com
-
Boehringer Ingelheim links up with GoodRx to offer its Humira biosimilar at a steep discount.
Amid rocky launch, Boehringer Ingelheim links up with GoodRx to offer its Humira biosimilar at a steep discount
fiercepharma.com
-
As biopharma companies and the U.S. government near the deadline of their drug price talks under the Inflation Reduction Act, Novartis CEO said the cost cuts “might be manageable” in the short term for the firm’s first few products to be included.
Novartis CEO sees IRA impact ‘manageable’ in short run, maintains midterm growth goal
fiercepharma.com
-
As myriad pharma industry attempts to challenge the Inflation Reduction Act fall flat, Johnson & Johnson is settling into a reality of pricing rebates and Medicare drug cost negotiations.
J&J keeps growth projections afloat as it braces for IRA price negotiation impact
fiercepharma.com
-
With a chemo-free regimen, Bayer hopes to reach the entire space of metastatic hormone-sensitive prostate cancer.
Bayer’s Nubeqa, en route to blockbusterland, clinches 2nd win in prostate cancer subtype
fiercepharma.com
-
The breadth of problems uncovered by the FDA is surprising considering the plant has been producing camrelizumab for the Chinese market since 2019.
Behind Hengrui's surprise FDA rejection: Scathing Form 483 lists litany of shortfalls at PD-1 drug plant
fiercepharma.com
-
CordenPharma will invest 900 million euros ($981 million) over the next three years to bolster its ability to manufacture GLP-1 peptides in Europe and the United States.
Swiss CDMO CordenPharma invests $981M to boost GLP-1 manufacturing capacity
fiercepharma.com
-
Eli Lilly and Company has choreographed another part of its Olympics-focused marketing campaign, partnering with seven-time medalist Simone Biles and her mom Nellie to promote the GLP-1 diabetes drug Mounjaro.
Eli Lilly vaults Simone Biles to head of Mounjaro ad campaign, partnering with Olympian for TV spot
fiercepharma.com
-
While patent cliffs are looming for many of biopharma’s top-selling products, the industry has enormous capacity to respond as “conditions for M&A are favorable,” according to a research note from Morgan Stanley.
Amgen, BMS and Merck have the most exposure as Big Pharma eyes $183B patent cliff: analyst
fiercepharma.com